aldosterone antagonist

The aldosterone system is directly targeted by spironolactone, an aldosterone antagonist.

Aldosterone antagonists: spironolactone, which is a competitive antagonist of aldosterone.

Potassium-sparing diuretics do not share any obvious chemical similarities, except for the steroid-structure of the aldosterone antagonists.

Aldosterone antagonists:

Diuretic options for inpatient treatment include aldosterone antagonists (usually spironolactone) and loop diuretics.

Treatment includes Spironolactone, a K+ sparing diuretic that works by acting as an aldosterone antagonist.

Spironolactone, an aldosterone antagonist.

Depending on cause and other factors, hyperaldosteronism can be treated by surgery and/or medically, such as by aldosterone antagonists.

Aldosterone antagonists are, as the name suggests, receptor antagonists at the mineralocorticoid receptor.

Aldosterone antagonists are not recommended as first-line agents for blood pressure, but spironolactone and eplerenone are both used in the treatment of heart failure.

An anti-mineralocorticoid, or an aldosterone antagonist, refers to a diuretic drug which antagonizes the action of aldosterone at mineralocorticoid receptors.

This results in a decrease in aldosterone release, which causes potassium-sparing-diuretic-like effects similar to those of the aldosterone antagonists, spironolactone and eplerenone.

Aldosterone antagonists are preferred for patients who can take oral medications and are not in need of an urgent volume reduction, with loop diuretics as additional therapy.

Canrenone (Contaren, Luvion) is an aldosterone antagonist with additional antiandrogen properties which is used as a diuretic in Europe.

Drugs used include: diuretic agents, vasodilator agents, positive inotropes, ACE inhibitors, beta blockers, and aldosterone antagonists (e.g.spironolactone).

Potassium canrenoate (INN) or canrenoate potassium (USAN), the potassium salt of canrenoic acid, is an aldosterone antagonist.

The aldosterone antagonist agent eplerenone has been shown to further reduce risk of cardiovascular death post-MI in patients with heart failure and left ventricular dysfunction, when used in conjunction with standard therapies above.

There is a significant evidence-practice gap in the treatment of CHF; particularly the underuse of ACE inhibitors and β-blockers and aldosterone antagonists which have been shown to provide mortality benefit.

In patients whose proteinuria is not controlled with ACE inhibitors, the addition of an aldosterone antagonist (i.e., spironolactone) or angiotensin receptor blocker (ARB) may further reduce protein loss.

It is a synthetic 17-lactone drug that is a renal competitive aldosterone antagonist in a class of pharmaceuticals called potassium-sparing diuretics, used primarily to treat heart failure, ascites in patients with liver disease, low-renin hypertension, hypokalemia and Conn's syndrome.

It is likely to be especially dangerous or fatal for patients taking other drugs that also may increase potassium levels, such as ACE inhibitors, angiotensin-II receptor agonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDs.